Fenghao Shi

Peking University — China

Medicine · Health Sciences

5h-index80citations14works1.62yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(5), Health Systems, Economic Evaluations, Quality of Life(4), Esophageal Cancer Research and Treatment(3), Pancreatic and Hepatic Oncology Research(2), Lung Cancer Treatments and Mutations(2)

Publications14 total

Cost-effectiveness analysis of the combination of low-dose nivolumab with triple metronomic chemotherapy for advanced head and neck squamous cell carcinoma in China
Frontiers in Oncology·2025Open Access
NMAsurv: An R Shiny application for network meta-analysis based on survival data
Research Synthesis Methods·2025Open Access
P43 IPDvariate: Reconstructing Patient Characteristics and Survival Data from Kaplan-Meier Curves for Subgroup Analysis
Value in Health·2025
Cost-effectiveness of CDK4/6 inhibitors for second-line HR+/HER2− advanced or metastatic breast cancer in China
Scientific Reports·2025· 5 citedOpen Access
Cost-effectiveness of universal genetic screening for familial hypercholesterolemia in young adults aged 18–40 years in China
BMC Medicine·2025· 3 citedOpen Access
Cost-effectiveness of durvalumab plus tremelimumab in combination with chemotherapy for the treatment of metastatic non-small-cell lung cancer from the US healthcare sector’s and societal perspectives
Frontiers in Pharmacology·2024· 1 citedOpen Access
Cost–effectiveness analysis of immune checkpoint inhibitors as first-line therapy in advanced biliary tract cancer
Immunotherapy·2024· 3 citedOpen Access
Cost-effectiveness analysis of PD-1 inhibitors as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma in China: an economic evaluation based on network meta-analysis
International Journal of Clinical Pharmacy·2024· 2 cited
Cost-effectiveness analysis of immune checkpoint inhibitors for first-line treatment of advanced esophageal squamous cell carcinoma based on fractional polynomial network meta-analysis
Research Square (Research Square)·2024Open Access
Impacts of adjustment of National Reimbursement Drug List on orphan drugs volume and spending in China: an interrupted time series analysis
BMJ Open·2023· 6 citedOpen Access
Adebrelimab plus chemotherapy vs. chemotherapy for treatment of extensive-stage small-cell lung cancer from the US and Chinese healthcare sector perspectives: a cost-effectiveness analysis to inform drug pricing
Frontiers in Pharmacology·2023· 7 citedOpen Access
Economic evaluation of tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China
Frontiers in Pharmacology·2022· 12 citedOpen Access
Cost-effectiveness of edaravone dexborneol versus edaravone for the treatment of acute ischemic stroke in China: Based on the TASTE study
Frontiers in Pharmacology·2022· 18 citedOpen Access
First-line treatments for advanced hepatocellular carcinoma: a network meta-analysis and cost-effectiveness analysis in China and the United States
Therapeutic Advances in Gastroenterology·2022· 23 citedOpen Access

Frequent Co-authors

Sheng Han(4), Ruizhe Liu(3), Hang Su(2), Yena Gan(2), Duoduo Li(2), Liping Kuai(2), Yijia Zhao(2), Jianhong Zhu(2), Junyan Wu(2), Kaifeng Qiu(2), Mingjun Rui(2), Kexin Sun(1), Shanshan Cao(1), Yue Guan(1), Meng Tang(1), Meina Zhao(1), Yu-Fan Jian(1), Bin Cui(1), Zhiyan Li(1), Jingwen Wang(1)